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Abstract
Background: Sample sizes for obstetrical trials are often based on the opinion of investigators about clinically
important effect size. We surveyed Canadian obstetricians to investigate clinically important effect sizes required
before introducing new treatments into practice to prevent preterm birth.
Methods: Questionnaires were mailed to practicing obstetricians, asking the magnitude of pregnancy prolongation
required to introduce treatments into practice. The three prophylactic treatments were of increasing invasiveness:
vaginal progesterone, intramuscular progesterone, and cervical cerclage. We also asked about the perceived most
relevant outcome measures for obstetrical trials and current obstetrical practice in preterm birth prevention.
Results: 544/1293(42.1%) completed questionnaires were received. The majority of respondents required one or
two weeks’ increase in length of gestation before introducing vaginal (372,77.1%), and intramuscular progesterone
(354,67.9%). At least three weeks increase was required before introducing prophylactic cervical cerclage(326,62.8%).
Clinicians who already used a treatment required a smaller difference before introducing it into practice.
Decreasing neonatal morbidity was cited as the most important outcome for obstetrical trials (349,72.2%).
Conclusion: Obstetricians would require a larger increase in treatment effect before introducing more invasive
treatments into practice. Although infant morbidity was perceived as a more important outcome, clinicians
appeared willing to change practice on the basis of prolongation of pregnancy, a surrogate outcome. We found
that there is not a single minimum clinically important treatment effect that will influence all practising clinicians:
rather the effect size that will influence physicians is affected by the nature of the treatment, the reported
outcome measure and the clinician’s own current clinical practice.
Keywords: Research design, Cross-sectional survey, Premature birth, Clinical trials as topic
Background
Clinical practice should be guided by evidence from well
designed clinical trials [1-3]. Unfortunately, the transfer
of knowledge from research into practice is often chal-
lenging, with a concomitant delay in the uptake of new
evidence [3,4]. Many reasons for the delay have been
proposed, including the inadequate dissemination of
research findings [5,6], and barriers caused by
entrenched physician beliefs [6-8].
Factors associated with research design also play an
important role. Randomised controlled trials are gener-
ally accepted as the “gold standard” for health research,
however studies that report statistically significant find-
ings can lack relevance for major stakeholders such as
clinicians, patients, and policy makers [9,10] and there-
fore fail to influence practice. Large sample sizes may
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any medium, provided the original work is properly cited.lead to findings that are statistically significant but clini-
cally irrelevant in their reflection of minor change
[11-13]. Small sample sizes lead to studies that are
underpowered to detect meaningful differences [12].
Additionally, sample size calculations may be based on
estimates of effect size that are not relevant to the study
being designed, or based on expert opinion [14]. Clinical
relevance is important for fixed and other more efficient
study designs (such as group-sequential designs [15]).
Concerns about clinical relevance of trials led to the
concept of “minimal clinically important difference”
(MCID) [16]. Originally applied to quality of life scales
that are difficult for clinicians to interpret directly,
MCID is defined as the lowest threshold of change
believed to be important by patients and clinicians
[13,16-19]. Other definitions have been suggested,
including “minimal important difference” [14] and
“really important difference” [20]. In treatment trials,
important differences are termed “clinically important
treatment effects” [21], however trial designers continue
to struggle with determining the appropriate size of
effect that would be sufficient to influence clinical prac-
tice. Many trialists choose to use an “opinion-based”
method to estimate clinically important treatment
effects, as opposed to “distribution approaches” which
use statistical methods based on the distributions of
scores of the measure of interest in control populations,
or “anchor approaches” that compare scores of measures
of interest with reference measures of known meaning
[22]. The “opinion approach” g a t h e r so p i n i o n so f
patients or experts [23], the investigators or their colla-
borators [24], however the effect size required to change
practice is known to be affected by a number of addi-
tional factors including clinical context [17], physician
background [25], and individual decision making pat-
terns [26]. For this reason, reliance on expert opinion to
determine clinically important effect size is unlikely to
reflect the generality of clinicians who will ultimately be
the recipients of the research findings.
In addition to other important factors such as the
mean and variance of the primary outcome, a plausi-
b l ee s t i m a t eo fe f f e c ts i z ew a s a critical consideration
in our estimation of sample size for a randomised trial
of vaginal progesterone versus placebo to prevent pre-
term birth in multiple pregnancy [27]. We wished our
trial to be as small as it could be to find the clinically
important treatment effect, and to ensure our trial
was feasible [26]. We knew that designing a large trial
that resulted in a change in pregnancy prolongation of
only one or two days (even if found statistically differ-
ent) would be unlikely to change clinical practice, but
we did not know the minimum difference that would
influence obstetrical practice. We therefore undertook
a survey of practicing obstetricians in Canada to
examine the minimum prolongation of pregnancy
necessary to change practice in hypothetical rando-
mised controlled trials of treatments to prevent pre-
term birth. Our study also examined the relative
importance of different outcome measures in clinical
trials.
Methods
This study, approved by the University of Calgary Con-
joint Health Research Ethics Board (Ethics ID 18809),
was a mailed questionnaire survey of all practicing
obstetricians in Canada conducted between March 2006
and June 2006. Current lists of registered obstetricians
and gynaecologists were obtained from the Colleges of
Physicians and Surgeons in each Canadian province (n
= 10) and territory (n = 3). The Ontario file excluded
physicians who had not consented to have contact infor-
mation released. The lists did not distinguish between
obstetricians and gynaecologists, and therefore question-
naires were sent to all those listed (n = 1531).
Each identified physician was mailed a structured
questionnaire. Two reminders were mailed at five week
intervals to non-responders. Recipients were first asked
to indicate if they did not provide care for pregnant
women and return the questionnaire without further
completion to avoid being sent further questionnaires.
The questionnaire was developed through discussion
among the research team, and piloted with obstetrical
residents (who were not therefore involved in the actual
survey). The questionnaire consisted of four sections
(Additional file 1). The first section contained three
vignettes describing clinical settings in which treatments
m i g h tb eu s e df o rw o m e na tr i s ko fp r e t e r mb i r t h ,a n d
asked about the minimum prolongation of pregnancy
that would be necessary for the respondent to introduce
preventative treatments into their practice:
Treatment 1: prophylactic dai l yp r o g e s t e r o n es u p p l e -
mentation, administered vaginally after 16 weeks gesta-
tional age. Progesterone is a hormone treatment that
may theoretically reduce the likelihood of preterm birth.
Risk factor: multiple gestation.
Treatment 2: prophylactic weekly progesterone sup-
plementation, administered intramuscularly after 16
weeks gestational age. Risk factors: history of preterm
birth or shortened cervix on ultrasound or positive fetal
fibronectin.
Treatment 3: prophylactic cervical cerclage placed
between 16-23 6/7 weeks gestational age. Cerclage is a
surgical procedure in which a stitch is placed in the cer-
vix to prevent it from opening in pregnancy. Risk factor:
shortened cervix on ultrasound.
The questionnaire provided three options for prolon-
gation of pregnancy: one, two or three weeks. Respon-
dents were asked to select the minimum prolongation
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into their clinical practice.
The next section asked about the most important clin-
ical outcome for justifying a change to clinical practice,
and whether the respondent would be willing to join
randomised trials that would investigate the same three
new prophylactic treatments. Respondents were also
asked about their current practice in relation to the
three treatments. Finally respondents were asked about
their age, length of time in practice, gender and practice
setting.
Statistical analyses were carried out using SAS 9.2
(SAS Institute Inc., Cary, NC), and were mainly
descriptive. Analyses were carried out on only com-
plete responses for each question, because there were
several question funnels which meant that some ques-
tions were not relevant to all respondents. For exam-
ple, in the sections about current clinical practice, it
would have been inappropriate to impute data for sub-
jects who did not respond because that section was
not relevant to them. Friedman test, a non-parametric
test comparing matched multiple groups, was used to
test whether within subjects the responses (prolonga-
tion of pregnancy needed to change practice) differed
significantly between the three interventions. Pearson
Chi Squared tests were used to examine differences
between groups (for example clinicians practicing in
different settings) in the proportion of respondents giv-
ing different choices of gestational prolongation
required to change practice.
Results
Response rate
Of 1531 questionnaires mailed out, 269 respondents did
not provide care to pregnant women or the question-
naires were returned because the addressees had moved
away. Thus questionnaires were presumed delivered to
1292 appropriate recipients, of whom 544 (42.1%)
returned completed questionnaires. The characteristics
of respondents are shown in Table 1.
Prolongation of pregnancy necessary to change practice
Respondents were asked to select the minimum prolon-
gation of pregnancy they believed was necessary to
introduce a preventative treatment into their clinical
practice for patients with risk factors for preterm birth
(Table 2). The majority of respondents would accept a
minimum increase in gestation of one week or two
weeks to introduce vaginal progesterone for women
with multiple gestations (372, 77.1%), and intramuscular
progesterone for women with singleton pregnancies and
a history of preterm birth or shortened cervix on ultra-
sound or positive fetal fibronectin (354, 67.9%). Prolon-
gation of pregnancy by at least 3 weeks was required by
the majority of respondents (326, 62.8%) before introdu-
cing prophylactic cervical cerclage for women with a
short cervix.
A Friedman test was carried out to compare, within
subjects, the responses for the three interventions. This
test found that responses for the three interventions dif-
fered significantly (×
2 = 291, df = 2, p <0 . 0 0 1 ) .T h e
mean ranks for the three treatments were: vaginal pro-
gesterone 1.75, intramuscular progesterone 1.85, cerc-
lage 2.39. This suggests that there was a tendency to
need a larger effect size to introduce intramuscular pro-
gesterone than vaginal progesterone, and there was a
need for a larger effect size to introduce cerclage.
Pearson Chi Squared tests were carried out to esti-
mate if there was a difference between respondents
from teaching hospitals versus those in community hos-
pitals in the level of evidence required to change their
practice for each of the three treatments. These tests
did not demonstrate differences between groups.
Current practice
Respondents were asked to describe their current obste-
trical practice relevant to the treatments in the scenarios
(Table 3).
Table 1 Characteristics of respondents
Characteristic Unit/details Description
(n = 544)
# missing
Age mean years 46 (SD 10) 9
Time in practice mean years 15 (SD 10) 4
Gender male
female
272 (50.6%)
266 (49.4%)
6
Practice setting urban/suburban
small town/rural
428 (80.0%)
107 (20.0%)
9
Hospital teaching
community
other
283 (52.2%)
232 (42.8%)
27 (5.0%)
2
Table 2 Prolongation of pregnancy required to introduce
new treatment into practice
Treatment used in clinical practice
Prolongation
of
pregnancy
required to
change
practice
Progesterone PV
in
multiples
(n = 544)
Progesterone IM
in
singletons
(n = 544)
Cerclage
(n = 544)
1 week 165 (31.5%) 138 (26.5%) 62 (11.9%)
2 weeks 207 (39.6%) 216 (41.5%) 131
(25.2%)
3 weeks 151 (28.9%) 167 (32.1%) 326
(62.8%)
Missing 21 23 25
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gesterone for women with multiple pregnancies, all of
whom would consider a history of previous preterm
delivery in their decision to treat. Among the 17 who
would use progesterone, vaginal treatment was pre-
scribed by 11 (64.7%), with the earliest start at a mean
of 12 weeks’ gestation and the latest stopping date at
mean 27 weeks.
Fifty-one respondents (9.7%) would prescribe proges-
terone for women with risk factors with singleton preg-
nancies, the majority of whom (49, 96.1%) would
consider a history of previous preterm delivery in their
decision to treat. Similarly, vaginal treatment was
favored by the majority (37 (72.5%), with the earliest
start at a mean of 13 weeks gestation and the latest
stopping at mean of 29 weeks.
Cerclage was a more widely used treatment, with 317
(62.8%) responding that they currently perform prophy-
lactic cervical cerclage. A number of risk factors influ-
enced the decision to place a cerclage: the most
common were short cervix (190, 59.9%), previous pre-
term delivery (176, 55.5%) and a diagnosis of
incompetent cervix (139, 43.8%). Cerclage would be per-
formed at the earliest at mean 13 weeks of gestation,
and at the latest at 22 weeks.
Pearson Chi Squared tests were carried out to esti-
mate if there was a difference between respondents who
currently used a treatment versus those who did not, in
the level of evidence required to change their practice.
The test for cerclage appeared to indicate that more
who currently used prophylactic cerclage would be will-
ing to accept a smaller effect size to introduce prophy-
lactic cerclage into practice (Table 4, ×
2 = 8.17, p =
Table 3 Current clinical practice - treatments for women at risk of preterm birth
Treatment used in clinical practice
Current clinical practice Progesterone
supplementation
in multiple pregnancies
(n = 544)
Progesterone
supplementation
in singleton pregnancies
(n = 544)
Cerclage
(n = 544)
use this treatment 17 (3.2%) 51 (9.7%) 317 (62.8%)
do not use this treatment 520 (96.8%) 476 (90.3%) 188 (37.2%)
missing 7 17 39
For ‘YES’ ONLY n = 17 n = 51 n = 317
Risk factors influencing decision *
previous preterm delivery 17 (100.0%) 49 (96.1%) 176 (55.5%)
hort cervix 12 (70.6%) 20 (39.6%) 190 (59.9%)
previous surgery 6 (35.3%) 8 (15.7%) 96 (30.3%)
previous PPROM 9 (52.9%) 24 (47.1%) 38 (12.0%)
positive FFN test 8 (47.1%) 12 (23.5%) 8 (2.5%)
multiple gestation not noted not noted 20 (6.3%)
incompetent cervix not noted not noted 139 (43.8%)
Route of administration favoured
*
oral 4 (23.5%) 14 (27.5%) not applicable
IM 3 (17.6%) 7 (13.7%)
vaginal 11 (64.7%) 37 (72.5%)
Earliest gestational age treatment
starts
mean
weeks
12 (SD 8)
range 2 to 30
missing 1
13 (SD 5)
range 4 to 24
missing 1
surgery not before:
13 (SD 2)
range 7 to 18
missing 23
Latest gestational
age treatment stops
mean
weeks
27 (SD 10)
range 12 to 36
missing 1
29 (SD 8)
range 12 to 36
missing 1
surgery not after: 22 (SD
4)
range 12 to 34
missing 47
Note: * respondents could check more than one risk factor and treatment type
Table 4 Current use of cerclage and minimum
prolongation of pregnancy required to introduce
prophylactic cerclage into practice
Current use of cerclage
Prolongation of pregnancy
required to change practice
Use cerclage
(n = 308)
Do not use cerclage
(n = 174)
1 week 44 (14.3%) 15 (8.6%)
2 weeks 86 (27.9%) 36 (20.7%)
3 weeks 178 (57.8%) 123 (70.7%)
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associated with effect size.
Feasibility of a trial
The majority of respondents stated that decreased fetal
morbidity (379, 72.2%) was the single most important
outcome measure that would justify introducing a new
treatment into their practice, rather than prolongation
of pregnancy (95, 18.1%) (Table 5).
The majority of respondents would be willing to take
part in a placebo controlled trial of vaginal progesterone
for women with multiple pregnancies (450, 84.1%), and
a trial of intramuscular progesterone for women with
singleton pregnancies (410, 77.5%) (Table 6). The most
commonly cited reason for not joining the multiple
gestation trial was having too few such patients in their
practice (26/85, (30.6%) (Table 6). The main concern
about the intramuscular progesterone trial was patient
discomfort associated with weekly intramuscular injec-
tions (32/119, 26.9%) (Table 6). By contrast, only a min-
ority of respondents would consider taking part in the
proposed cerclage trial (239, 45.5%) (Table 5): the main
reason for not wishing to join such a trial was concerns
about the invasive nature of the cerclage itself (110/288,
38.2%) (Table 6).
Discussion
The determination of a suitable estimate of effect size is
notoriously difficult [26]. Our mailed survey of all Cana-
dian obstetricians attempted to estimate the clinically
important treatment effect required to change practice
in the prevention of preterm birth, in order to increase
the likelihood that our research would be relevant, with
the potential to influence clinical practice. Our study
found that responding clinicians were willing to identify
an increase in duration of pregnancy that they believed
would change their practice. The small amount of miss-
ing data indicated that respondents found the clinical
scenarios plausible.
Our study found that minimal clinically important
treatment effect was associated with the invasiveness of
the treatment, and current clinical practice of the
respondents. A one or two week prolongation of preg-
nancy was the minimum effect size required by around
70% of obstetricians to introduce new progesterone
treatments into their practice for treating women at risk
of preterm birth. Cerclage, a more invasive treatment,
required a larger minimum effect size: a three week
Table 5 Feasibility of trials
What would be the best outcome measure for a trial? (n = 544)
Outcome Response
prolongation of gestation 95 (18.1%)
decreased fetal morbidity 379
(72.2%)
decreased fetal mortality 50 (9.5%)
decreased maternal
morbidity
1 (0.2%)
missing 19
Would you take part in a trial?
Vaginal Progesterone
in multiple
pregnancies
(n = 544)
Progesterone IM in
singleton
pregnancies
(n = 544)
Cerclage
(n = 544)
yes 450 (84.1%) 410 (77.5%) 239
(45.5%)
no 85 (15.9%) 119 (22.5%) 288
(54.6%)
missing 9 15 17
Table 6 Reasons given for not taking part in a trial
Trial Reasons for not
joining
Vaginal progesterone in
women with multiple
pregnancies
n=8 5
Small numbers/rural 26 (30.6%)
Concerns re
intervention
11 (12.9%)
Concerns re trial design 10 (11.8%)
Retiring soon 9 (10.6%)
Lack of resources 9 (10.6%)
Do not do research 6 (7.1%)
Not recorded 14 (16.5%)
IM progesterone in women
with singleton pregnancies
with
risk factors for preterm birth
n = 119
Concerns re
intervention
32 (26.9%)
Lack of resources 23 (19.3%)
Small numbers/rural 18 (15.1%)
Concerns re trial design 9 (7.6%)
Retiring soon 9 (7.6%)
Do not do research 4 (3.4%)
Sufficient evidence 2 (1.7%)
Not recorded 22 (18.5%)
Cerclage in women with risk
factors for preterm birth
n = 288
Concerns re
intervention
110
(38.2%)
Sufficient evidence 38 (13.2%)
Do not do cerclage 32 (11.1%)
Concerns re trial design 28 (9.7%)
Small numbers/rural 21 (7.3%)
Lack of resources 10 (3.5%)
Retiring soon 8 (2.8%)
Do not do research 4 (1.4%)
Not recorded 37 (12.8%)
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ability of the treatment also influenced the minimum
important treatment effect: clinicians who already had
access to cerclage were willing to accept a smaller effect
size to utilize this treatment.
The impact of the choice of effect size may best be
illustrated using the parameters we employed when cal-
c u l a t i n gt h es a m p l es i z ef o ro u rp r o g e s t e r o n et r i a l[ 2 7 ] .
For that study, we used local data from a two year per-
iod to estimate the usual (untreated) mean and standard
deviation gestational age of delivery for multiple preg-
nancies. Sample size calculations using a power of 80%
and two-sided significance level of 0.05, would estimate
sample sizes as follows: to detect a three week differ-
ence, a sample of 36 (18 per randomised group) would
be required; for two weeks, the sample size would be 78
( 3 9p e rg r o u p ) ;f o ro n ew e e k ,t h es a m p l es i z ew o u l db e
156 (78 per group). If the three week effect size was
chosen, and therefore the smaller sample size was used,
a real difference between treated and control groups of
one or two weeks would not be identified as a signifi-
cant difference. These examples clearly show that the
choice of clinically important treatment effect has a
practical effect on the design, conduct and clinical rele-
vance of the study. Applying these examples to our
hypothetical scenarios, it is clear that a trial of cerclage
versus no cerclage would be smaller in size than a trial
of a progesterone treatment versus placebo.
The principal goal of prophylactic treatment for
women at risk of preterm labour is to improve the out-
come for the neonate by reducing morbidity and mor-
tality. The consequences of even late preterm birth are
considerable, with worse developmental outcomes and
academic difficulties up to seven years of age compared
to term infants [28]. In our questionnaire study, the
majority of respondents (72.2%) clearly recognised this
by stating that decreased fetal morbidity was the most
important outcome to justify changing clinical practice.
Despite this, in our hypothetical scenarios where clini-
cians were asked to consider changing their clinical
practice on the basis of prolongation of pregnancy, all
but 4% were willing to make a choice based on that out-
come. It therefore appears that clinicians would be will-
ing to accept a surrogate outcome on which to base a
change in clinical practice. This is an important point: a
trial that measures impact of a treatment on fetal or
neonatal morbidity, even in a trial examining preterm
birth where adverse neonatal events would be expected,
will need to be far larger than one that measures impact
on pregnancy duration, where every pregnancy will have
an outcome [29]. In addition, the definition of a ‘neona-
tal morbidity’ composite outcome is fraught with diffi-
culty, and is open to misinterpretation by clinicians and
patients [29]. Thus the choice of effect size and choice
o fo u t c o m ew i l li m p a c to nt h es i z ea n de x p e n s eo fa
clinical trial. Both of these choices will also impact on
the adoption of trial findings into clinical practice.
We were interested about the feasibility of trials of
treatments to prevent preterm birth. Concern for the
patient and increasing invasiveness of the intervention
impacted on respondents’ decisions about taking part in
a trial. The majority of respondents would be willing to
take part in both hypothetical progesterone trials. The
most frequently cited reason for declining to take part
in the multiple trial was feasibility (lack of suitable
cases), while concern about the intervention (for exam-
ple patient discomfort) was most commonly cited for
the intramuscular progesterone trial. Concern about
cerclage itself was a common reason for not wishing to
take part in a trial, although 13.2% believed that there
was already sufficient evidence to use prophylactic cerc-
lage in women with a short cervix. We did not lead clin-
icians in their reason for not wishing to take part in
each trial, rather leaving them to provide text answers
to open-ended questions. Therefore we believe the
responses were those that mattered most to the
clinicians.
The design of our questionnaire could be criticised for
a number of reasons. Firstly, the questionnaire described
three hypothetical scenarios, including different risk fac-
tors for preterm birth. Although designed to represent
clinical experience, we do not know whether the
responses would reflect actual practice. Secondly, in the
clinical scenarios, we used a forced choice method that
asked clinicians to choose a one, two or three week pro-
longation of pregnancy as the outcome for the hypothe-
tical treatments. It is possible that clinicians would be
willing to accept a shorter increase or would prefer a
longer increase in gestation before changing their prac-
tice. We set the earliest gestational age for treatment at
16 weeks, and the longest duration of pregnancy as 33
weeks and 4 days [30,31], for each hypothetical prolon-
gation of pregnancy. Thus it is possible that the choice
of clinically important increase in duration of pregnancy
may have been affected by our descriptions. These sce-
narios and choices were necessarily complex, reflecting
situations commonly encountered by obstetricians who
manage high risk pregnancies.
Much research relevant to the prevention of preterm
birth has been published since our survey was carried
out, reflecting the ongoing interest and importance of
this topic. Recent publications conclude that, in appro-
priately selected women with high-risk singleton preg-
nancies, progesterone can reduce preterm birth before
33 weeks’ gestation [32], and cerclage can reduce pre-
term birth and improve neonatal outcome [33]. Trials of
progesterone in multiple pregnancies have failed to pre-
vent preterm birth [34], most likely because of a
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placental mass, and greater stretching of uterine muscle
[35]. Nonetheless, preterm birth remains the most con-
cerning perinatal problem for obstetricians, and there-
fore new progesterone trials continue to be undertaken
[36], and the search for new effective treatments
continues.
Our survey of all obstetricians was challenging and
would not be feasible for all trials, partly because such
surveys are costly and time consuming, and partly
because clinicians would be plagued by many similar
questionnaires, leading to declining response rates and
possible bias in the results. In the future, we believe that
a more limited survey of a random sample of practicing
clinicians would be more appropriate. In our study,
however, obstetricians were willing to respond to our
fairly complex questionnaire: we achieved a response
rate of 42.1% after only two reminders, similar to
response rates from other surveys of clinical practice
[25,37,38]. Our respondents came from a range of clini-
cal settings and had a range of experience. Our large
number of responses (n = 544) leads us to believe that
our findings are more representative of clinician beliefs
than the more usual practice of identifying the mini-
mum clinically important treatment effect by discussion
with trial collaborators [25] or experts [23].
Conclusion
The importance of our study lies in the continuing need
to undertake meaningful and efficient randomized trials
that are designed to support clinical practice [2,3]. Such
trials must provide clinically important differences
rather than merely statistically significant differences,
and the results should be available in a timely way
[7,13]. To be timely, trials should be designed to be as
small as realistically possible to obtain clinically relevant
results. Our study developed a method that was able to
estimate the clinically important difference needed to
design our randomised trial [27]. Clinical trialists must
make the additional effort to estimate the minimum
clinically important treatment effect that is relevant to
practicing clinicians. Without this effort, trials will con-
tinue to fail to influence clinical practice.
Additional material
Additional file 1: Questionnaire.
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